IMNN News & Events

In a regulatory filing, the company stated, "On June 29, 2026, Jeffrey Church informed Imunon of his intent to retire from the position of interim Chief Financial Officer, a position he has held since January of 2026, effective July 1, 2026. To help ensure a smooth transition of his responsibilities to his successor, Church and the company agreed that he will continue in a consulting role with the company. As a result of Mr. Church's retirement, effective July 1, 2026, the company appointed Josh Blacher to serve as the company's new interim Chief Financial Officer under a master services agreement, dated June 24, 2026, between the company and Danforth Health, Inc., a financial advisory services firm. Mr. Blacher will serve as the company's principal financial officer and principal accounting officer."

Imunon announced that the independent Data Monitoring Committee, or IDMC, has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy in women with newly diagnosed advanced ovarian cancer. "We are very pleased that the iDMC has recommended continuation of the landmark OVATION 3 clinical trial without modification, representing another important validation of the remarkable efficacy and safety data previously reported and further indicating the potential for IMNN-001 to represent a historic advance in the treatment of ovarian cancer," said Stacy Lindborg, president and chief executive officer of Imunon. "We remain ahead of our anticipated schedule in patient enrollment and this recommendation by the iDMC brings new levels of momentum to our efforts to advance this trial as rapidly as possible."

"Enrollment in our pivotal Phase 3 OVATION 3 trial continues ahead of plan, reflecting patient interest and strong conviction among principal investigators and the broader medical community in IMNN-001's therapeutic potential," said Stacy Lindborg, President and Chief Executive Officer of IMUNON. "Coupled with the unprecedented overall survival benefit observed in our Phase 2 study and an aligned path to BLA filing, IMNN-001 is well positioned to potentially transform the standard of care in advanced ovarian cancer."